Could a cancer drug slow lung scarring? new trial tests anlotinib for IPF

NCT ID NCT05828953

Ongoing Disease control Sponsor: First Affiliated Hospital of Wenzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether anlotinib, a drug currently used for cancer, can help people with idiopathic pulmonary fibrosis (IPF) or progressive fibrosis-interstitial lung disease. The study involves 30 adults aged 40-85 and measures changes in lung function over 52 weeks. Participants take anlotinib or a placebo daily in a 2-weeks-on, 1-week-off cycle.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anlotinib (a drug that may slow lung scarring)
What this could lead to: If it works, this could point toward a new treatment to slow lung function decline in people with IPF or related lung scarring diseases.
What could go wrong: This is a small, early Phase 2 trial with only 30 participants. It may not show clear benefit, and anlotinib has not been proven safe or effective for these conditions yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis interstitial lung disease pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASES

Contacts and locations

Locations

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, 325000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.